List of Tables
    Table 1. Primary Sclerosing Cholangitis Treatment Market Opportunities & Trends in Global Market
    Table 2. Primary Sclerosing Cholangitis Treatment Market Drivers in Global Market
    Table 3. Primary Sclerosing Cholangitis Treatment Market Restraints in Global Market
    Table 4. Key Players of Primary Sclerosing Cholangitis Treatment in Global Market
    Table 5. Top Primary Sclerosing Cholangitis Treatment Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Primary Sclerosing Cholangitis Treatment Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Primary Sclerosing Cholangitis Treatment Product Type
    Table 9. List of Global Tier 1 Primary Sclerosing Cholangitis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Primary Sclerosing Cholangitis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Primary Sclerosing Cholangitis Treatment Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Primary Sclerosing Cholangitis Treatment Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Primary Sclerosing Cholangitis Treatment Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Primary Sclerosing Cholangitis Treatment Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2023-2028
    Table 30. Allergan Corporate Summary
    Table 31. Allergan Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 32. Allergan Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 33. Glenmark Corporate Summary
    Table 34. Glenmark Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 35. Glenmark Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 36. Impax Laboratories Corporate Summary
    Table 37. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 38. Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 39. Mylan Corporate Summary
    Table 40. Mylan Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 41. Mylan Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 42. Teva Pharmaceuticals Corporate Summary
    Table 43. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 44. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 45. Dr. Falk Pharma Corporate Summary
    Table 46. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 47. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 48. Daewoong Pharmaceutical Corporate Summary
    Table 49. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 50. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 51. Epic Pharma Corporate Summary
    Table 52. Epic Pharma Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 53. Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 54. Mitsubishi Tanabe Pharma Corporate Summary
    Table 55. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 56. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 57. Lannett Corporate Summary
    Table 58. Lannett Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 59. Lannett Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 60. Bruschettini Corporate Summary
    Table 61. Bruschettini Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 62. Bruschettini Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 63. Shanghai Pharma Corporate Summary
    Table 64. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 65. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 66. Grindeks Corporate Summary
    Table 67. Grindeks Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 68. Grindeks Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 69. Acorda Therapeutics Corporate Summary
    Table 70. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 71. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 72. Gilead Sciences Corporate Summary
    Table 73. Gilead Sciences Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 74. Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 75. Intercept Pharmaceuticals Corporate Summary
    Table 76. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 77. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 78. Shire Plc Corporate Summary
    Table 79. Shire Plc Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 80. Shire Plc Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 81. NGM Biopharmaceuticals Corporate Summary
    Table 82. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 83. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 84. Conatus Pharmaceuticals Corporate Summary
    Table 85. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 86. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 87. Durect Corporation Corporate Summary
    Table 88. Durect Corporation Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 89. Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 90. Sirnaomics Corporate Summary
    Table 91. Sirnaomics Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 92. Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
    Table 93. Shenzhen HighTide Biopharmaceuticals Corporate Summary
    Table 94. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offerings
    Table 95. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Primary Sclerosing Cholangitis Treatment Segment by Type in 2021
    Figure 2. Primary Sclerosing Cholangitis Treatment Segment by Application in 2021
    Figure 3. Global Primary Sclerosing Cholangitis Treatment Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Primary Sclerosing Cholangitis Treatment Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Primary Sclerosing Cholangitis Treatment Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue in 2021
    Figure 8. By Type - Global Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
    Figure 12. US Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
    Figure 16. Germany Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 17. France Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
    Figure 24. China Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 28. India Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
    Figure 30. Brazil Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue Market Share, 2017-2028
    Figure 33. Turkey Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Primary Sclerosing Cholangitis Treatment Revenue, (US$, Mn), 2017-2028
    Figure 37. Allergan Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Glenmark Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Mylan Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 45. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 46. Lannett Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 47. Bruschettini Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 48. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 49. Grindeks Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 50. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 51. Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 52. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 53. Shire Plc Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 54. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 55. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 56. Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 57. Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 58. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)